---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-040521"
form_type: "8-K"
ticker: "FBIO"
cik: "0001429260"
company_name: "Fortress Biotech, Inc."
filed_at: "2024-03-28T23:59:59+00:00"
generated_at: "2026-06-04T05:58:56.723572+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Fortress Biotech 2023 rev $84.5M; net loss $(68.7)M; DFD-29 PDUFA Nov 4, 2024

## Summary
- Record consolidated net revenue $84.5M in 2023, up from $75.7M in 2022; net loss $(68.7)M ($8.47/share) vs $(94.6)M ($15.97).
- Cash $83.4M at Dec 31, 2023, down $97.6M YoY; raised ~$34.9M in 2023/early 2024 offerings.
- FDA accepted DFD-29 NDA for rosacea; PDUFA date Nov 4, 2024; up to 4 NDA/BLA decisions in next 18 months.
- Cosibelimab BLA received CRL in Dec 2023 (manufacturing only); resubmission expected for 2024 approval.
- Journey Medical product net revenues fell to $59.7M from $71.0M; total net rev $79.2M (+7%).

## SEC filing metadata
- accession: 0001104659-24-040521
- form_type: 8-K
- ticker: FBIO
- cik: 0001429260
- company_name: Fortress Biotech, Inc.
- filed_at: 2024-03-28T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1429260/000110465924040521/0001104659-24-040521-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1429260/000110465924040521/tm2410123d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-040521
- JSON: https://secwatch.observer/filing/0001104659-24-040521.json
- Plain text: https://secwatch.observer/filing/0001104659-24-040521.txt

## Key facts
- Earnings Releases
  Fortress Biotech, Inc. reported the full year ended December 31, 2023 results: revenue Record consolidated net revenue of $84.5 million.
  - Period: the full year ended December 31, 2023
  - Revenue: Record consolidated net revenue of $84.5 million
  - Result: reported results
  source text: Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights Record consolidated net revenue of $84.5 million for full-year 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1429260/000110465924040521/0001104659-24-040521-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.